Want to see GB:IDHC full AI Analyst Report?
IDHC Stock Chart & Stats
$0.55
$0.00(0.00%)
At close: 4:00 PM EDT
$0.55
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.48 - $0.84
Previous CloseN/A
Volume192.12K
Average Volume (3M)1.13M
Market Cap
$279.04M
Enterprise Value$199.41M
Total Cash (Recent Filing)$1.96B
Total Debt (Recent Filing)$1.68B
Price to Earnings (P/E)10.4
Beta0.64
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.31%
Share Statistics
EPS (TTM)2.59
Shares Outstanding581,326,300
10 Day Avg. Volume3,240,517
30 Day Avg. Volume1,132,414
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)6.10
Price to Sales (P/S)2.63
P/FCF Ratio14.92
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue0.02
Enterprise Value/Gross Profit0.05
Enterprise Value/Ebitda0.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.73
Revenue Forecast (FY)$9.82B
Bulls Say, Bears Say
Bulls Say
Broad-based GrowthStrong growth across revenue, testing volumes, and patients indicates expanding demand and deeper utilization of the diagnostic platform. This combination supports operating leverage, strengthens the company’s market position, and provides a durable base for continued earnings growth over the next several quarters.
Healthy ProfitabilityProfit growth outpaced or broadly tracked strong revenue expansion while gross margin improved, demonstrating effective procurement, cost control, and operating leverage. Sustained profitability gives IDH internal funding capacity and supports continued investment in branches, technology, and broader diagnostic services.
Scalable Network ExpansionThe rapidly expanding branch network increases patient access, referral reach, and testing capacity while reinforcing IDH’s national footprint. Its scale can support cross-service adoption and more efficient logistics, creating a durable competitive advantage as the company adds facilities and services.
Bears Say
Working-capital PressureHigher receivables and inventory absorb cash and make reported earnings less immediately convertible into liquidity. If these balances remain elevated, they could constrain funding flexibility and reduce the cash available for expansion, debt reduction, or shareholder distributions over coming quarters.
Saudi LossesSaudi expansion is generating rapid growth but has not yet reached break-even, so additional branches may require ongoing investment before contributing positively to group earnings. This creates execution risk and could temper consolidated margins until utilization and patient volumes mature.
Geopolitical ExposureThe ongoing Sudan conflict has materially limited operations and demonstrates that regional disruption can affect IDH’s geographic footprint. Continued constraints may reduce contribution from the market and require management attention, while broader regional uncertainty could also affect activity and patient volumes.
Integrated Diagnostics Holdings News
IDHC FAQ
What was Integrated Diagnostics Holdings PLC’s price range in the past 12 months?
Integrated Diagnostics Holdings PLC lowest share price was $0.48 and its highest was $0.83 in the past 12 months.
What is Integrated Diagnostics Holdings PLC’s market cap?
Integrated Diagnostics Holdings PLC’s market cap is $279.04M.
When is Integrated Diagnostics Holdings PLC’s upcoming earnings report date?
Integrated Diagnostics Holdings PLC’s upcoming earnings report date is Nov 12, 2026 which is in 16 days.
How were Integrated Diagnostics Holdings PLC’s earnings last quarter?
Integrated Diagnostics Holdings PLC released its earnings results on Nov 14, 2024. The company reported $0.008 earnings per share for the quarter.
Is Integrated Diagnostics Holdings PLC overvalued?
According to Wall Street analysts Integrated Diagnostics Holdings PLC’s price is currently Overvalued.
Does Integrated Diagnostics Holdings PLC pay dividends?
Integrated Diagnostics Holdings PLC pays a Notavailable dividend of $0.009 which represents an annual dividend yield of 5.31%. See more information on Integrated Diagnostics Holdings PLC dividends here
What is Integrated Diagnostics Holdings PLC’s EPS estimate?
Integrated Diagnostics Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Integrated Diagnostics Holdings PLC have?
Integrated Diagnostics Holdings PLC has 581,326,300 shares outstanding.
What happened to Integrated Diagnostics Holdings PLC’s price movement after its last earnings report?
Integrated Diagnostics Holdings PLC reported an EPS of $0.008 in its last earnings report. Following the earnings report the stock price went up 1.154%.
Which hedge fund is a major shareholder of Integrated Diagnostics Holdings PLC?
Currently, no hedge funds are holding shares in GB:IDHC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Integrated Diagnostics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.66%
12-Months-Change
Fundamentals
Return on Equity
39.61%
Trailing 12-Months
Asset Growth
―
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Integrated Diagnostics Holdings PLC
Integrated Diagnostics Holdings plc (IDHC.L) functions as a leading consumer healthcare enterprise, offering a wide array of medical diagnostic services directly to its clientele. The company's comprehensive service catalog features around 2,000 distinct diagnostic examinations, spanning specialized fields such as immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, cytogenetics, histopathology, and radiology. Geographically, IDHC has established operations across Egypt, Jordan, Sudan, and Nigeria. As of December 30, 2021, its infrastructure included an extensive network of 452 laboratory branches. The organization was founded in 1979 and maintains its corporate headquarters in Saint Helier, Jersey.
Technical Analysis
Bioventix
―
EKF Diagnostics Holdings
―
Genedrive
―
Omega Diagnostics
―
Abingdon Health PLC
―